The election of all directors follows the candidate nomination system in accordance with the Procedures for Election of Directors. Matters related to the professional qualifications, shareholding, determination of independence, nomination and election methods, and other requirements for independent directors shall all be handled in accordance with the relevant regulations of the securities regulatory authority.
All independent directors were elected in accordance with the aforementioned regulations. This process included submission to the board of directors for discussion and approval, the submission of relevant supporting documents to the company during the announced nomination period, and presenting the roster of director candidates at the shareholders’ meeting for election.
Director , Representing
Oneness Biotech Co., Ltd.
Member of
Sustainable Development
and Nominating Committee
Oneness Biotech Co., Ltd.
Member of
Sustainable Development
and Nominating Committee
Convener of Audit Committee,
Remuneration Committee,
and Sustainable Development
and Nominating Committee
Member of Audit Committee
and Remuneration Committee
Member of Audit Committee
and Remuneration Committee
Member of Audit Committee,
Remuneration Committee,
and Sustainable Development
and Nominating Committee
Member of Audit Committee,
Remuneration Committee,
and Sustainable Development
and Nominating Committee
Member of Audit Committee
and Remuneration Committee
Specific Management Objectives of the Diversity Policy
The selection conditions of the Company’s Directors are not limited to gender, age, ethnicity, and nationality, and the Company also focuses on gender equality for the composition.
The Company explicitly stipulates in its Corporate Governance Best Practice Principles that the composition of the Board of Directors shall take diversity into consideration. In addition to the principle that directors concurrently serving as company managers should not exceed one-third of the total number of Board seats, the Company has formulated appropriate diversity policies based on its operational characteristics, business model, and development needs. Furthermore, starting from 2024, the Board shall include no fewer than one director of each gender.
Status of Achievement of the Diversity Policy
Among the directors of the sixth Board term, five directors are aged 71 or above, two are aged between 61 and 70, one is aged between 51 and 60, and one is under the age of 40. Currently, none of the Board members concurrently serves as the Company manager. All Board members possess professional knowledge and skills relevant to the Company’s required industry or financial background.
Independent directors account for two-thirds of the total Board seats, and three seats are held by female directors. The Company has effectively implemented the diversity policies and objectives as set forth in its Corporate Governance Best Practice Principles.
To enhance corporate governance, the Board as a whole possesses capabilities including, but not limited to, operational judgment, accounting and financial analysis, business management, crisis management, industry knowledge, international market perspective, leadership, decision-making, and risk management knowledge and competencies, as outlined below.
|
Item
Director’s Name
|
Gender |
Operational |
Accounting |
Operation |
Crisis |
Industry |
International |
Leadership |
Decision-making |
Risk |
|
Pan-Chyr Yang |
Male |
✔ |
|
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
|
Tsu-Der Lee |
Male |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
|
Che-An Chou |
Male |
✔ |
|
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
|
Der-Tsai Lee |
Male |
✔ |
|
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
|
Fei-Peng Li |
Male |
✔ |
|
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
|
Shu-Hui |
Female |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
|
Li-Ching Chen |
Female |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
|
Shi-Yu Hsiang |
Female |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
|
Shih-Tsung Chang |
Male |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
✔ |
According to the company’s “Rules for Performance Evaluation of Board of Directors,” which was approved by Board of Directors on May 17, 2022. The performance evaluation of the Board of Directors and functional committees is conducted annually in accordance with these measures. The Board of Directors’ performance evaluation includes at least five main aspects:
To valuate the performance of the functional committees, the evaluation items include at least the following five main aspects:
Evaluation result
FY2024
Additionally, the company has disclosed the “Rules for Performance Evaluation of Board of Directors” under the Governance – Major Internal Policies for reference.
Summary of Communication Between Independent Directors and CPAs (2025)
| Date | Item | Key Points of Communication | Outcomes |
|---|---|---|---|
| 2025/2/25 | Pre-Audit Committee Meeting |
|
|
| 2025/5/9 | Pre-Audit Committee Meeting |
|
|
| 2025/8/8 | Pre-Audit Committee Meeting |
|
|
| 2025/11/10 | Pre-Audit Committee Meeting Private Session |
|
|
Summary of Communication Between Independent Directors and internal audit supervisor (2025)
| Date | Item | Key Points of Communication | Outcomes |
|---|---|---|---|
| 2025/2/25 | Pre-Audit Committee Meeting |
|
|
| 2025/5/9 | Pre-Audit Committee Meeting |
|
|
| 2025/8/8 | Pre-Audit Committee Meeting |
|
|
| 2025/11/10 | Pre-Audit Committee Meeting Private Session |
|
|
The company places great importance on succession planning for key management positions, including President (CEO) and Vice Presidents, in order to ensure long-term business sustainability and organizational resilience. In evaluating successors, in addition to operational management capabilities, professional expertise, and outstanding performance, candidates must also demonstrate alignment with the company’s core values and core competencies—integrity, innovation, professionalism, and a strong results orientation.
There are currently 12 key management personnel at the managerial level and above. Each has a defined job description and career development plan, along with a designated deputy who is trained as a potential successor. The company leverages its existing performance evaluation system to assess the suitability of potential successors, thereby facilitating succession planning and execution. The Human Resources Department is responsible for formulating and implementing the succession plan and reports to the Board of Directors on an annual basis.
Specific Measures and Implementation Practices Include:
醣基生醫股份有限公司
2017年9月27日登錄興櫃市場交易 (6586:TT)
公司所在地
台北,台灣
公司設立日期
2013
登錄公開市場
2017
公司官網
https://www.chopharma.com/cn/index.html